Biomarkers are used to indicate the biological state of a process, pathogenic process or therapeutic action. Biomarkers facilitate understanding the development of a chronic disease, relationship between exposure to environmental chemicals and identification of subgroups of people who are relatively at high risk of developing disease. Continued development in related technologies such as genomics, proteomics and imaging system has accelerated the development of biomarkers. With the complexity of Central Nervous System (CNS), it is considered that biomarkers will play a vital role in identifying several neurodegenerative diseases at early stage, provide more accurate diagnosis and better treatment.
The global market for Central Nervous System biomarkers has been growing rapidly over the past two decades and is expected to continue further under the influence of increased governmental support, rapidly increasing aging population and advancements in supporting technologies such as genomics, proteomics and imaging technologies.
The world is witnessing a rapid growth in aging population leading to high prevalence of many CNS disorders such as Parkinson’s, multiple sclerosis and Alzheimer’s disease. The Aging Research Center, Karoliska Institute, Sweden suggests that approximately 24 million are affected with Alzheimer’s disease worldwide. These diseases incur significant burden on society, to overcome these burdens governments are supporting private and public laboratories by funding to continue their development process. United States government has proposed to spend USD 140.8 billion in the fiscal 2013 to support research and development program across the country.
View Exclusive Global Strategic Business Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1622
Geographically, North America represents the largest market as healthcare infrastructure ismore advanced as compared to other regions around the globe and it also has a large population base suffering from CNS diseases. The emerging markets including India, china, Brazil and Mexico are poised to show substantial growth due to continuously improving healthcare facilities in these nations.
Some of the prominent players engaged in the development and marketing of biomarkers are AbaStar MDX, Apitope International, ExonHit Therapeutics, Metabolon Inc., Myriad RBM, OPKO Health, Thermo Fisher Scientific and Osta Biotechnologies.
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453